Psychedelic Funding, Public Markets, and M&A in 2025

Psychedelic Alpha tracks investment across public and private psychedelics companies, and reviews how 2025 fundraising, public market activity, and dealmaking looked. The report highlights that 2025 saw $1.2 billion raised by psychedelics companies, with a major surge in Q4. It cites three large public financings early in Q4 2025: AtaiBeckley closing a $149.5M offering in late October, Helus Pharma closing a $175M direct offering on the final day of October, and Definium Therapeutics (formerly MindMed) closing a $259M public offering in early November. The analysis connects financing activity with public market performance, uses market comparisons and visualizations (including a Sankey chart), and then turns to M&A and partnerships across the psychedelics sector.